Medroxyprogesterone acetate
مدروکسی‌پروژسترون
🚻 Genito Urinary System And Sex HormonesProgestin
Market / country: 🇺🇸 USA
Provera (US)
🧮 Dose calculator
Secondary amenorrhoea · Regimen source: FDA Medroxyprogesterone · Dosage and Administration
- • For optimal secretory transformation: 10 mg daily for 10 days. Withdrawal bleeding usually 3–7 days after stopping. FDA Medroxyprogesterone · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Undiagnosed genital bleeding; breast cancer or hormone-dependent neoplasia; current or past DVT/PE or arterial thromboembolism; liver disease; pregnancy; anaphylaxis to the drug. FDA Medroxyprogesterone · Contraindications
- ⚠️ Boxed warning: with oestrogen, increased risk of DVT, PE, stroke, MI, breast cancer and dementia in postmenopausal women. FDA Medroxyprogesterone · Boxed Warning
Formulations
- 10 mg tablet (scored) — tablet 🇺🇸 USA FDA Medroxyprogesterone · How Supplied
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA Medroxyprogesterone · CONTRAINDICATIONS
“Known or suspected pregnancy.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Medroxyprogesterone · Precautions/Warnings – Nursing Mothers
“Medroxyprogesterone acetate should not be used during lactation.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Medroxyprogesterone · Precautions/Warnings – Pediatric Use
“Medroxyprogesterone acetate tablets are not indicated in children.”
- 👴 Older adultsDangerous / avoid
Label: serious warning or avoid in older adults. FDA Medroxyprogesterone · Boxed Warning
“Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA040159
- DailyMed (FDA label)FDA Medroxyprogesterone
- MedlinePlus (NIH)Estrogen and Progestin (Hormone Replacement Therapy)Medroxyprogesterone
- WHO ATC/DDDG03DA02
- Darooyab (Iran)Medroxyprogesterone-Acetate
🇮🇷 Registered in Iran Darooyab · G-3275/Medroxyprogesterone-Acetate
Dosage forms with Iranian generic codes, per Darooyab.
- 00791 · MEDROXYPROGESTERONE ACETATE 150MG/1ML AMP · آمپول مدروکسی‌پروژسترون استات ۱۵۰ میلی‌گرم / ۱ میلی‌لیتر
- 13657 · MEDROXYPROGESTERONE ACETATE 150MG/3ML VIAL · ویال مدروکسی‌پروژسترون استات ۱۵۰ میلی‌گرم / ۳ میلی‌لیتر
- 00789 · MEDROXYPROGESTERONE ACETATE 250MG TAB · قرص مدروکسی‌پروژسترون استات ۲۵۰ میلی‌گرم
- 00793 · MEDROXYPROGESTERONE ACETATE 500MG/2.5ML AMP · آمپول مدروکسی‌پروژسترون استات ۵۰۰ میلی‌گرم / ۲٫۵ میلی‌لیتر
- 00790 · MEDROXYPROGESTERONE ACETATE 500MG/5ML VIAL · ویال مدروکسی‌پروژسترون استات ۵۰۰ میلی‌گرم / ۵ میلی‌لیتر
- 00792 · MEDROXYPROGESTERONE ACETATE 5MG TAB · قرص مدروکسی‌پروژسترون استات ۵ میلی‌گرم
- 06066 · MEDROXYPROGESTRON 500MG/3.3ML VIAL · ویال مدروکسیپروجسترون ۵۰۰ میلی‌گرم / ۳٫۳ میلی‌لیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Medroxyprogesterone · How SuppliedFDA Medroxyprogesterone · Dosage and AdministrationFDA Medroxyprogesterone · ContraindicationsFDA Medroxyprogesterone · Boxed WarningFDA Medroxyprogesterone · CONTRAINDICATIONSFDA Medroxyprogesterone · Precautions/Warnings – Nursing MothersFDA Medroxyprogesterone · Precautions/Warnings – Pediatric UseFDA Medroxyprogesterone · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-3275/Medroxyprogesterone-Acetate
- Clinical review⚠ Unverified